The study of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) has been greatly facilitated by the use of in vitro culture systems similar to those used to study normal hematopoietic stem and progenitor cells (HSPCs). In vitro culture has been used to study the basic biology of these diseases and as a platform for the screening of compounds, such as tyrosine kinase inhibitors and other candidate therapeutics, on primary patient-derived cells.
Unfortunately, in vitro culture and studies of primary leukemic HSPCs can be impeded by the limited access to patient samples, a problem that may be compounded by poor yield and/or viability of cryopreserved samples after thawing. In this live webinar, Dr. Leon Lin will describe some of the challenges commonly associated with the existing, non-standardized leukemic cell culture system and discuss solutions to some of the technical issues with the current system.
Have you faced challenges in culturing or expanding leukemic stem and progenitor cells? Register now to submit your question.
Leon Lin, PhD
Scientist, STEMCELL Technologies
Live Webinar: Troubleshooting In Vitro Expansion of Leukemic Cells
Monday June 24, 2019 | 11:00 a.m. PST | 2:00 p.m. EST | 7:00 p.m. UTC
If you are unable to attend the live webinar, please register and a link will be sent to you with the recorded version.
- Applications of leukemic cell culture and expansion in basic biology and drug discovery
- Current systems for ex vivo culture of AML and CML stem and progenitor cells
- Overcoming common technical challenges with the current system
Dr. Lin is a Research & Development Scientist at STEMCELL Technologies, in the Hematopoietic Research Group. He received his PhD, which focused on investigating novel therapeutic targets and microRNAs in chronic myeloid leukemia, from the University of British Columbia under the mentorship of Dr. Xiaoyan Jiang in the Terry Fox Laboratory at the BC Cancer Agency. Leon was the recipient of multiple doctoral fellowships and travel grants and has published several first-authored papers in peer-reviewed journals, in addition to abstracts for ISEH, ASH, and ESH. Since 2016, he has worked at STEMCELL, developing culture systems and assays tailored specifically for leukemic stem and progenitor cells.